Improving how prevention is delivered
Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.
AVAC’s work supports:
Meeting
Meeting
report
This document outlines a focused plan for LEN for PrEP rollout over the next few years, specifying priorities by stakeholder and evaluating volume and pricing strategies. The report as a whole details a coordinated response to this historic opportunity to ensure rapid implementation, equitable access, and sustainable impact.
infographic
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
infographic
To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.
Integrating PrEP and contraception in a single pill to expand choices.
A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it.
Overcoming access challenges to new PrEP options.
Federal AIDS Policy Partnership Research Working Group urges Congressional leaders to support the restraining order preventing the National Institutes of Health (NIH) from unlawfully stripping funds that sustain cutting-edge medical and public health research at universities and research institutions nationwide.